- Home
- YMAB
as 05-09-2025 4:00pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Upcoming Earnings Alert:
Get ready for potential market movements as Y-mAbs Therapeutics Inc. YMAB prepares to release earnings report on 13 May 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 218.4M | IPO Year: | 2018 |
| Target Price: | $18.73 | AVG Volume (30 days): | 216.5K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.84 - $17.47 | Next Earning Date: | 05-13-2025 |
| Revenue: | $87,685,000 | Revenue Growth: | 3.38% |
| Revenue Growth (this year): | -4.04% | Revenue Growth (next year): | 18.83% |
Stock Insider Trading Activity of Y-mAbs Therapeutics Inc. (YMAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Mar 7 '25 | Sell | $5.23 | 10,810 | $56,536.30 | 202,721 | |
| Rossi Michael J | YMAB | PRESIDENT & CEO | Mar 7 '25 | Sell | $5.20 | 3,917 | $20,368.40 | 137,083 |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewswire
4 days ago
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Zacks
10 days ago
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
Zacks
11 days ago
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
GlobeNewswire
12 days ago
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
Simply Wall St.
13 days ago
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures
GlobeNewswire
15 days ago
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
MT Newswires
a month ago
Top Premarket Decliners
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.